Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-0042-116460 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Immunotherapy on the Care Patterns and Outcomes of Patients with Advanced Hepatocellular Carcinoma.
Clin Res Hepatol Gastroenterol
January 2025
Department of Surgery, Division of Surgical Oncology, Roger Williams Medical Center. 825 Chalkstone Ave, Providence, RI 02908, USA. Boston University School of Medicine. 72 E Concord St, Boston, MA 02118, USA. Electronic address:
Background: Modern immunotherapy with checkpoint inhibitors revolutionized cancer treatment and outcomes. This study aims to demonstrate how immunotherapy has impacted the national landscape of systemic treatment and palliative care in advanced hepatocellular carcinoma (HCC).
Methods: Retrospective cohort selecting patients from the U.
Advances in personalized medicine and Systems Biology have introduced probabilistic models and error discovery to cardiovascular care, aiding disease prevention and procedural planning. However, clinical application faces cultural, technical, and methodological hurdles. Patient autonomy remains essential, with shared decision-making (SDM) gaining importance in managing complex cardiovascular treatment options.
View Article and Find Full Text PDFJust-in-time adaptive ecological momentary assessment and ecological momentary interventions for posttraumatic psychopathology in the modern age of technology.
Psychol Trauma
January 2025
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina.
Objective: One technique for tailoring interventions and matching evidence-based procedures to idiographic problems is just-in-time adaptive approaches, also referred to as ecological momentary intervention. These technology-based approaches involve real-time delivery of evidence-based skills when most needed, which can be tailored to individual data inputs. The current article reviews just-in-time adaptive ecological momentary assessment (JITA-EMA; Schneider et al.
View Article and Find Full Text PDFNew and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making.
BioDrugs
January 2025
Department of Neurology, Neuroscience Clinical Research Center (NCRC) and Integrated Myasthenia Gravis Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117, Charitéplatz 1, Germany.
Myasthenia gravis (MG) is a rare autoimmune disease characterised by exertion-induced muscle weakness that can lead to potentially life-threatening myasthenic crises. Detectable antibodies are directed against specific postsynaptic structures of the neuromuscular junction. MG is a chronic condition that can be improved through therapies, but to date, not cured.
View Article and Find Full Text PDFIs there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy.
Curr Opin Oncol
January 2025
Department of Medical Oncology, Institut Jules Bordet - Université Libre de Bruxelles (ULB).
Purpose Of Review: This review aims to explore the evolving management strategies for stage III melanoma, focusing on the comparative effectiveness of traditional surgical approaches like complete lymph node dissection (CLND) versus modern adjuvant therapies. It also examines the latest evidence on the efficacy, risks, and complications of these strategies, emphasizing the role of shared decision-making between patients and clinicians.
Recent Findings: Recent clinical trials and meta-analyses, including the MSLT-II and DeCOG-SLT studies, have demonstrated that CLND may not significantly improve survival outcomes in melanoma patients with sentinel lymph node biopsy (SLNB)-positive status.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!